Immune checkpoint inhibition for the treatment of metastatic breast cancer with high tumor mutational burden: Real world clinical and genomic correlates of response.

Authors

Nicholas Mai

Memorial Sloan Kettering Cancer Center, New York, NY

Nicholas Mai , Anton Safonov , Antonio Marra , Yuan Chen , Sarat Chandarlapaty , Pedram Razavi , George Plitas

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

Non–Subtype-Specific Breast Cancer Therapies

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr 1078)

DOI

10.1200/JCO.2024.42.16_suppl.1078

Abstract #

1078

Poster Bd #

Abstract Disclosures

FEATURED

Immune checkpoint inhibition for the treatment of metastatic breast cancer with high tumor mutational burden: Real world clinical and genomic correlates of response.

Authors

Nicholas Mai

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Poster Details

Meeting

Session Type

Session Title

Track

Sub Track

Citation

DOI

Abstract #

Poster Bd #

Similar Posters

Poster

OPERA-01: A randomized, open-label, phase 3 study of palazestrant (OP-1250) vs standard-of-care for patients with ER+, HER2- advanced or metastatic breast cancer after endocrine therapy and CDK4/6 inhibitors.

Poster

Characterization of estrogen receptor mutant breast cancer in 3D cell culture.

Poster

Real world outcomes of sequential ADC therapy in metastatic breast cancer: Patients treated with sacituzumab govitecan and trastuzumab deruxtecan.

Poster

Association of HER2 expression in advanced urothelial carcinoma (aUC) and treatment outcomes with immune checkpoint inhibitors and enfortumab vedotin.